Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Consensus Rating of “Buy” from Analysts

Stoke Therapeutics, Inc. (NASDAQ:STOK) has received a consensus recommendation of “Buy” from the ten analysts that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. The average 1 year target price among analysts that have covered the stock in the last year is $21.29.

A number of brokerages recently issued reports on STOK. Cantor Fitzgerald restated an “overweight” rating on shares of Stoke Therapeutics in a research note on Tuesday, December 10th. Leerink Partners assumed coverage on Stoke Therapeutics in a report on Monday, October 14th. They set an “outperform” rating and a $18.00 target price for the company. Chardan Capital initiated coverage on shares of Stoke Therapeutics in a report on Friday, December 20th. They issued a “buy” rating and a $24.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $35.00 price objective on shares of Stoke Therapeutics in a report on Wednesday. Finally, Leerink Partnrs raised shares of Stoke Therapeutics to a “strong-buy” rating in a report on Friday, October 11th.

Insider Buying and Selling

In related news, General Counsel Jonathan Allan sold 13,666 shares of the business’s stock in a transaction on Monday, December 9th. The shares were sold at an average price of $13.61, for a total value of $185,994.26. Following the completion of the sale, the general counsel now owns 21,476 shares of the company’s stock, valued at approximately $292,288.36. The trade was a 38.89 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Barry Ticho sold 13,945 shares of the stock in a transaction on Friday, December 6th. The shares were sold at an average price of $12.78, for a total transaction of $178,217.10. Following the transaction, the insider now directly owns 47,332 shares in the company, valued at approximately $604,902.96. The trade was a 22.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 62,849 shares of company stock valued at $809,421. Corporate insiders own 11.30% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of STOK. Quest Partners LLC acquired a new stake in Stoke Therapeutics during the 2nd quarter worth $29,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in Stoke Therapeutics during the second quarter worth about $123,000. Intech Investment Management LLC acquired a new position in Stoke Therapeutics during the third quarter worth about $160,000. The Manufacturers Life Insurance Company grew its stake in Stoke Therapeutics by 16.7% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 13,964 shares of the company’s stock valued at $189,000 after acquiring an additional 1,994 shares in the last quarter. Finally, Mesirow Financial Investment Management Inc. acquired a new stake in Stoke Therapeutics in the 3rd quarter valued at about $192,000.

Stoke Therapeutics Stock Performance

Shares of STOK stock opened at $9.00 on Monday. The firm has a market capitalization of $476.70 million, a price-to-earnings ratio of -4.29 and a beta of 0.95. The stock’s 50-day simple moving average is $11.91 and its 200-day simple moving average is $13.04. Stoke Therapeutics has a fifty-two week low of $4.09 and a fifty-two week high of $17.58.

Stoke Therapeutics (NASDAQ:STOK) last issued its quarterly earnings results on Tuesday, November 5th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.05. The business had revenue of $4.89 million for the quarter, compared to analyst estimates of $3.46 million. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. As a group, equities analysts forecast that Stoke Therapeutics will post -2.03 earnings per share for the current year.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.